Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 10, 2013, Pages 4047-4054

  Chieffo, Carla ^a   Cook, David ^b   Xiang, Qinfang ^a   Frohman, Lawrence A ^c  

^a Endo Health Solutions Inc   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LONG ACTING DRUG; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CHOLECYSTITIS; CHOLELITHIASIS; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG IMPLANT; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RHINOPHARYNGITIS;

ACROMEGALY; ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INFUSION PUMPS, IMPLANTABLE; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; TREATMENT OUTCOME;

EID: 84885194977     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2262     Document Type: Article

References (15)

1. Melmed S, Casanueva F, Cavagnini F., et al Consensus statement: medical management of acromegaly. Eur J Endocrinol. 2005; 153: 737-740.
2. Ezzat S. Living with acromegaly. Endocrinol Metab Clin NorthAm. 1992; 21: 753-760.
3. Eastman RC, Gorden P, Glatstein E., Roth J. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 1992; 21: 693-712.
4. Lamberts SW, Oosterom R, Neufeld M, del Pozo E. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab. 1985; 60: 1161-1165.
5. Bauer W, Briner U, Doepfner W., et al SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133-1140.
6. Feelders RA, Hofland LJ, van Aken MO, et al Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 2009; 69: 2207-2226.
7. Ezzat S, Forster MJ, Berchtold P, Redelmeier D.A., Boerlin V., Harris AG Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994; 73: 233-240.
8. Schlegel PN. A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer. BJU Int. 2009; 103(SUPPL. 2):7-13.
9. Eugster EA, Clarke W, Kletter G.B., et al Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007; 92: 1697-1704.
10. Schlegel PN. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J Urol. 2006; 175: 1353-1358.
11. Ware JE, Kosinski MM, Dewey JE How to Score Version Two of the SF-36® Health Survey. Lincoln, RI: QualityMetric Incorporated; 2006.
12. Joseph S, Li G, Lindholm E., et al A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy. Pancreas 2010; 39: 964-966.
13. Novartis Pharmaceuticals Corp. 2010 Sandostatin LAR® depot [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
14. IPSEN, Pharma Biotech. 2011 Somatuline® Depot (lanreotide) Injection 60 mg/0.2 mg [prescribing information]. Signes, France: IP-SEN, Pharma Biotech
15. Gadelha MR, Chieffo C, Bai SA, Hu X, Frohman LA. A subcutaneous octreotide hydrogel implant for the treatment of acromegaly. Endocr Pract. 2012; 18: 870-881.